The adhesion barrier market industry is projected to grow from USD 0.643 billion in 2023 to USD 1.123 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.22% during the forecast period (2023 - 2032).
The adhesion barrier market is witnessing steady growth globally, driven by rising surgical procedures and the prevalence of post-operative complications. These barriers prevent internal organs and tissues from sticking together after surgery, reducing the risk of adhesions. Factors such as an aging population, increased surgical interventions, and advancements in medical technology contribute to market expansion. Biodegradable materials are gaining prominence due to their reduced risk of adverse effects. Key players in the market are investing in research and development to innovate products and improve efficacy. With a focus on patient outcomes and healthcare cost reduction, the adhesion barrier market is poised for continuous expansion.
The Adhesion Barrier Market is experiencing significant growth, driven by innovations such as Seprafilm and Interceed adhesion barriers. Seprafilm adhesion barrier, known for its efficacy in reducing postoperative adhesions, has become a cornerstone in surgical practices worldwide. Its bioresorbable membrane acts as a physical barrier, preventing the formation of adhesions between tissues following surgery. Surgeons rely on Seprafilm to minimize the risk of complications such as bowel obstructions and infertility, improving patient outcomes and reducing healthcare costs.
Similarly, Interceed adhesion barriers have garnered attention for their role in preventing adhesions in various surgical procedures. Its unique oxidized regenerated cellulose (ORC) composition provides a temporary barrier between tissues, reducing the likelihood of adhesion formation and subsequent complications. With increasing awareness among surgeons about the benefits of adhesion barriers, the demand for products like Seprafilm and Interceed is poised to rise further.
The market for adhesion barriers is driven not only by advancements in technology but also by the growing number of surgical procedures worldwide. As healthcare systems prioritize patient safety and quality of care, the adoption of adhesion barriers is expected to accelerate. Seprafilm and Interceed stand out as leading solutions in this evolving landscape, offering surgeons effective tools to enhance surgical outcomes and improve patient recovery.
Segmentation
The global market for adhesion barrier has been segmented into product, formulation, severity, and application.
Side-effect, the worldwide market for bond hindrance has been portioned into manufactured grip boundaries and normal attachment obstructions. The manufactured attachment obstructions are additionally isolated into hyaluronic corrosive, recovered cellulose, and polyethylene glycol. Manufactured attachment obstructions represented the biggest piece of the pie because of a few benefits over regular bond boundaries, including high biocompatibility, bioresorbable property, and cost-viability of these items. The regular grip obstructions are additionally sectioned into collagen and protein, fibrin.
By detailing, the worldwide bond hindrance has been portioned into film, gel, and fluid. Film based attachment obstructions are projected to hold the biggest portion of the overall industry because of better taking care of qualities and demonstrated positive outcomes. Driving makers for these items are J&J, Sanofi, and others. Gel-based grip obstructions are made out of polyethylene oxide and sodium carboxymethylcellulose, with defensive action. Fluid based grip hindrances are meant to make a site-explicit obstruction on an objective.
By severity, the global market for adhesion barrier has been segmented into mild adhesion and severe adhesion. Mild adhesion was the largest market share. According to a study of 122 patients, only three patients were found to have switched from mild to severe adhesion. Example of mild adhesion includes filmy and avascular. Severe adhesion is expected to hold the least market share. Example of severe adhesion includes organized, cohesive, vascular, and dense.
By application, the global market for adhesion barrier has been described by gynecological surgeries. Gynecological surgeries are projected to have the largest market share due to a large number of gynecological procedures, and many women are likely to experience post-surgical adhesions. It is estimated that 90 % of patients undergo main abdominal surgery and that between 55% and 100% of females undergo pelvic surgery develop adhesions.
Regional Analysis
Regionally, the global adhesion barrier market has been segmented into the Americas, Europe, and Asia Pacific.
The Americas drove the grip obstruction market in 2019 and is supposed to keep on ruling the market all through the gauge period. This is because of the presence of an enormous number of clinical gadget firms, an ascent in innovative work, an expansion in laparoscopy methodology, and countless patients. In excess of 400,000 laparotomies are directed every year in the United States alone for little inside obstacle.
Europe is projected to hold the second-biggest offer because of expanded utilization of cutting-edge innovations and expanded item advancement by existing makers.
The Asia Pacific is projected to rise at the highest rate of growth during the study period. This is due to widely populated countries such as China, India, Indonesia, Pakistan, and Bangladesh, growing gynecological procedures, and increasing government initiatives to raise awareness of women's related diseases.
Key Players
The global adhesion barrier companies are Johnson & Johnson, Atrium Medical Corporation (A Part of Getinge Group), Betatech Medical, R. Bard, FzioMed, Innocoll Holdings, Anika Therapeutics, Integra LifeSciences Holdings Corporation, Baxter International, MAST Biosurgery, Normedi Nordic., Sanofi.
Related Reports:
Asia-Pacific Interventional Cardiology
For More Information, Please Visit @ Market Research Future
